📊 MCLE Key Takeaways
Is MCLE a Good Investment? Thesis Analysis
Medicale Corp demonstrates critical financial distress with zero revenue, negative stockholders' equity of -$145.4K, and persistent negative cash flows. The company is technically insolvent with liabilities exceeding assets, indicating severe operational failure and insolvency risk.
Why Buy MCLE? Key Strengths
- No strengths identified
MCLE Investment Risks to Consider
- Zero revenue with no visible business operations
- Negative stockholders' equity indicating technical insolvency
- Negative operating cash flow of -$6.7K with no ability to fund operations
- Total liabilities of $145.4K against zero assets
- No cash reserves to service debt or continue operations
- Complete absence of profitability metrics across all categories
Key Metrics to Watch
- Revenue generation and return to operations
- Stockholders' equity recovery and path to positive net worth
- Operating cash flow stabilization and return to positive territory
MCLE Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
MCLE Profitability Ratios
MCLE vs Default Sector
How Medicale Corp. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MCLE Overvalued or Undervalued?
Based on fundamental analysis, Medicale Corp. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MCLE Balance Sheet & Liquidity
MCLE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Medicale Corp.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
MCLE Growth Metrics (YoY)
MCLE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | N/A | -$8.3K | $0.00 |
| Q3 2022 | N/A | -$6.6K | $0.00 |
| Q2 2022 | N/A | -$6.6K | N/A |
| Q1 2022 | N/A | -$11.5K | N/A |
| Q2 2021 | N/A | -$18.7K | N/A |
| Q1 2021 | N/A | -$11.5K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MCLE Capital Allocation
MCLE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Medicale Corp. (CIK: 0001827855)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MCLE
What is the AI rating for MCLE?
Medicale Corp. (MCLE) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MCLE's key strengths?
Claude: .
What are the risks of investing in MCLE?
Claude: Zero revenue with no visible business operations. Negative stockholders' equity indicating technical insolvency.
What is MCLE's revenue and growth?
Medicale Corp. reported revenue of $0.0.
Does MCLE pay dividends?
Medicale Corp. does not currently pay dividends.
Where can I find MCLE SEC filings?
Official SEC filings for Medicale Corp. (CIK: 0001827855) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MCLE's EPS?
Medicale Corp. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MCLE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Medicale Corp. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MCLE stock overvalued or undervalued?
Valuation metrics for MCLE: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MCLE stock in 2026?
Our dual AI analysis gives Medicale Corp. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MCLE's free cash flow?
Medicale Corp.'s operating cash flow is $-6.7K, with capital expenditures of $0.0.
How does MCLE compare to other Default stocks?
Vs Default sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 1.8).